A randomized controlled Phase Ib trial of the malaria vaccine candidate GMZ2 in African children
Research output: Contribution to journal › Journal article › Research › peer-review
GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical trials, one in naïve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a target population for future malaria vaccine efficacy trials.
Original language | English |
---|---|
Journal | P L o S One |
Volume | 6 |
Issue number | 7 |
Pages (from-to) | e22525 |
ISSN | 1932-6203 |
DOIs | |
Publication status | Published - 2011 |
ID: 33889016